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Truncating variants in the titin gene (TTNtv) are the most common genetic contributor to dilated cardiomyopathy (DCM), found in 15% of unselected DCM patients 1 and up to 27% of end-stage DCM patients. 2 As such, identification of reproducible and clinically informative genotype-phenotype correlations offers potential for precision genotype-guided management of DCM. Titin is the largest human protein. It is expressed in cardiac and skeletal muscle, and is integral to sarcomere structure and function. In cardiomyocytes, one titin molecule spans the hemi-sarcomere from the Z disc to the M line. Titin has roles in maintaining sarcomere integrity, force transmission, stretch sensing, and signalling. It is composed of four modular domains (Z disc, I band, A band, and M line), with the extensible I band contributing to sarcomere relaxation and contraction.
Dilated cardiomyopathy has been shown to have a familial basis in 20-30% of cases. 3 A genetic basis to DCM has been proposed in 40% of cases, 4 although with a more critical evaluation of the genes linked to DCM the true percentage is likely to be smaller. The identification of TTNtv in DCM, however, has substantially increased the number of informative genetic tests. In the clinic, these data are particularly useful for informing cascade screening. What are the mechanisms underpinning any differences in disease expression and how responsive is TTNtv DCM compared with other causes of DCM to usual therapy?
The higher prevalence of TTNtv in patients with end-stage heart failure in earlier studies has previously led to the conclusion that TTNtv are associated with a more severe phenotype and could inform prognosis. There have now been a number of TTNtv DCM phenotype studies, 1,2,6-8 including our own recently published study of 83 TTNtv DCM patients amongst a cohort of >700 DCM patients. other clear phenotypic differences between positive and negative TTNtv groups. Patients were followed up for a median of 45 months for the primary composite endpoint of death, cardiac transplant, heart failure hospitalization, and major ventricular arrhythmias. In line with our study, the authors did not detect a difference in short-and long-term outcome survival between TTNtv-positive and TTNtvnegative DCM patients. TTNtv in DCM certainly do not have the adverse effect size on mortality associated with LMNA cardiomyopathy, the only currently clinically actionable genetic variant in DCM. There may be a more moderate effect, and this will need to be analysed in larger cohort studies.
On subgroup analysis, TTNtv DCM patients appeared to have more life-threatening ventricular arrhythmias. This is therefore the first study to demonstrate a long-term arrhythmic phenotype of TTNtv DCM, albeit one which is not associated with adverse survival. As there were only 28 arrhythmic events across the cohort, including 9 in patients with TTNtv, multivariable analysis of the predictors of an arrhythmic phenotype was not possible and so the current findings will need replication and validation in a larger cohort of patients before any potential mainstream clinical application. Mechanistically, subset endomyocardial biopsy data identified increased interstitial fibrosis in TTNtv-positive patients compared with TTNtv-negative patients, and this may partly account for the relatively increased arrhythmic burden though, as interstitial fibrosis is a reactive and dynamic process, it is not yet clear if this is a TTNtv-specific finding or reflects other circumstances such as stage of disease, concurrent medication, or environmental factors.
Biopsy data also enabled the authors to perform an exploratory analysis of possible environmental modifiers of the TTNtv DCM phenotype such as viral load and inflammation, as well as systemic disease and toxin exposure. They found that the presence of an additional environmental risk factor in a patient with TTNtv DCM (present in 17 patients with TTNtv DCM) was associated with a trend to an increased risk of long-term arrhythmias (P = 0.047). Unfortunately, conclusive analysis of the role of environmental modifiers was not possible with the sample size and event rate in this study. It is still highly plausible that the phenotype and prognosis of TTNtv DCM will be altered in the presence of an environmental modifier; this could also account for some of the differences in expressivity seen in families. This remains an interesting and active area of research, but one that will need larger, multicentre studies of outcome in TTNtv DCM.
Insights from myocardial RNA sequencing demonstrated up-regulation of the mitochondrial electron transport chain in TTNtv hearts. This is a striking finding, mirroring recent findings in a pre-clinical model. 5 Further work will be important to elucidate the mechanistic link between increased mitochondrial activity and TTNtv. So how does one harness this information in a clinical setting. Clinically, the study by Verdonschot et al. 12 makes an important contribution, adding to our understanding of the clinical phenotype of TTNtv DCM, that will help guide further study of DCM pathobiology, but does not yet support a change to current guidelines or clinical practice. The novel association with long-term arrhythmias identified in this study is interesting and will require replication in a larger cohort. Future studies should also focus on defining the subpopulations of DCM with a higher risk of arrhythmia to elucidate more fully any potential interaction. For example, TTNtv may have a role to play in risk stratification within a higher risk subset of DCM patients, such as those with low left ventricular ejection fraction and mid-wall fibrosis. It is notable in this study that patients with TTNtv DCM had more severely impaired ventricular function than found in previous studies.
Finally, a major unmet need in DCM risk stratification is in the identification of the relative importance of different risk variables across demographic, clinical, imaging, and genetic domains. A collective effort is now needed for multicentre collaboration to evaluate multiparametric risk stratification in DCM.
